George Jay Goldsmith Sells 9,621 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock

COMPASS Pathways plc (NASDAQ:CMPS) major shareholder George Jay Goldsmith sold 9,621 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $8.29, for a total transaction of $79,758.09. Following the completion of the transaction, the insider now directly owns 3,966,052 shares of the company’s stock, valued at $32,878,571.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

George Jay Goldsmith also recently made the following trade(s):

• On Tuesday, April 16th, George Jay Goldsmith sold 23,881 shares of COMPASS Pathways stock. The shares were sold at an average price of $8.53, for a total transaction of $203,704.93.
• On Monday, April 1st, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.96, for a total transaction of $230,720.00.
• On Tuesday, March 12th, George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock. The shares were sold at an average price of $10.58, for a total transaction of $166,529.20.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS opened at $8.54 on Wednesday. COMPASS Pathways plc has a one year low of $5.01 and a one year high of $12.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33. The firm has a market cap of $528.97 million, a price-to-earnings ratio of -3.57 and a beta of 2.39. The stock’s fifty day moving average price is $9.46 and its two-hundred day moving average price is $8.53.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). On average, equities analysts forecast that COMPASS Pathways plc will post -2.4 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on CMPS. Morgan Stanley started coverage on COMPASS Pathways in a research note on Monday, April 1st. They issued an “overweight” rating and a $30.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a report on Friday, March 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of COMPASS Pathways in a report on Tuesday, April 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways presently has an average rating of “Buy” and a consensus target price of $47.40.

Institutional Investors Weigh In On COMPASS Pathways

Hedge funds and other institutional investors have recently made changes to their positions in the business. Quest Partners LLC bought a new position in COMPASS Pathways during the 4th quarter worth $33,000. Bailard Inc. acquired a new stake in COMPASS Pathways during the third quarter worth about $88,000. Conservest Capital Advisors Inc. bought a new position in COMPASS Pathways in the 4th quarter valued at about $91,000. TAP Consulting LLC raised its position in shares of COMPASS Pathways by 14.7% in the 3rd quarter. TAP Consulting LLC now owns 12,845 shares of the company’s stock valued at $95,000 after buying an additional 1,645 shares in the last quarter. Finally, EWA LLC bought a new stake in shares of COMPASS Pathways during the 4th quarter worth approximately $107,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.